WordNet

the 20th letter of the Roman alphabet (同)t
an agranulocytic leukocyte that normally makes up a quarter of the white blood cell count but increases in the presence of infection (同)lymph cell
a tough youth of 1950s and 1960s wearing Edwardian style clothes (同)Teddy boy

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. BおよびTリンパ球の正常な発生 normal b and t lymphocyte development
2. 特発性CD4陽性リンパ球減少症 idiopathic cd4 lymphocytopenia
3. 大顆粒T細胞リンパ球性白血病の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of t cell large granular lymphocyte leukemia
4. T細胞受容体シグナル伝達 t cell receptor signaling
5. 成人T細胞性白血病/リンパ腫の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of adult t cell leukemia lymphoma

Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection.

Sunshine JE1, Larsen BB2, Maust B2, Casey E2, Deng W2, Chen L2, Westfall DH2, Kim M2, Zhao H2, Ghorai S2, Lanxon-Cookson E2, Rolland M3, Collier AC4, Maenza J4, Mullins JI5, Frahm N6.
Journal of virology.J Virol.2015 Oct 15;89(20):10303-18. doi: 10.1128/JVI.01876-15. Epub 2015 Jul 29.
To understand the interplay between host cytotoxic T-lymphocyte (CTL) responses and the mechanisms by which HIV-1 evades them, we studied viral evolutionary patterns associated with host CTL responses in six linked transmission pairs. HIV-1 sequences corresponding to full-length p17 and p24 gag were
PMID 26223634

Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.

Koster BD1, de Gruijl TD, van den Eertwegh AJ.
Current opinion in oncology.Curr Opin Oncol.2015 Sep 8. [Epub ahead of print]
PURPOSE OF REVIEW: In this review, we focus on the recent findings and future challenges in cancer treatment with immune checkpoint inhibitors.RECENT FINDINGS: Major progress has been made in recent years as the first immune checkpoint inhibitors are approved by the US Food and Drug Administration f
PMID 26352539

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.

Kawano K1, Tsuda N1, Waki K2, Matsueda S3, Hata Y3, Ushijima K1, Itoh K3, Yamada A2, Kamura T1.
Cancer science.Cancer Sci.2015 Sep;106(9):1111-7. doi: 10.1111/cas.12729. Epub 2015 Jul 22.
A feasibility study was performed to evaluate the immunological efficacy and safety of a personalized peptide vaccine (PPV) for cervical cancer patients who have received platinum-based chemotherapy. A total of 24 patients with standard chemotherapy-resistant cervical cancer, including 18 recurrent
PMID 26122553